Test Price
2,800 AEDโ Home Collection Available
PRKRA Gene DYT16 Genetic Test in UAE โ 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
This definitive genetic test for DYT16 dystonia employs Next-Generation Sequencing (NGS) to detect pathogenic variants in the PRKRA gene with 99.9% diagnostic sensitivity. Processed in an ISO 9001:2015-certified laboratory, the service includes VIP Mobile Phlebotomy with temperature-controlled cold-chain home collection (available daily from 8 AM to 11 PM), telephonic clinical guidance from a DHA-licensed genetics consultant, and direct insurance billing verification via WhatsApp. All procedures comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring absolute confidentiality and regulatory integrity.
Test Price: 2,800 AED | Turnaround Time: 14โ21 Business Days
Test Overview & Methodology
The PRKRA gene DYT16 Genetic Test screens for pathogenic variants associated with young-onset dystonia-parkinsonism (DYT16), enabling precise diagnosis, carrier detection, and informed reproductive planning. This advanced NGS-based analysis replaces older single-exon sequencing approaches with comprehensive full-gene coverage and superior clinical accuracy.
| Feature | PRKRA DYT16 NGS (Our Test) | Single-Exon Sequencing (Alternative) |
|---|---|---|
| Precision | 99.9% sensitivity; full gene coverage | <85% sensitivity; partial coverage |
| Method | NGS with Sanger confirmation | Sanger sequencing only |
| Turnaround Time | 14โ21 business days | 6โ8 weeks |
| Sample Requirement | Peripheral whole blood, FTA card, or extracted DNA | Fresh whole blood only |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Genetic testing for dystonia provides families with definitive answers, but results must always be interpreted alongside clinical presentation and neurological evaluation. A pathogenic variant in the PRKRA gene confirms susceptibility to DYT16; however, a negative result does not entirely exclude the disorder when clinical signs are present. Every test is preceded by thorough genetic counselling to ensure patients fully understand the implications for themselves and their family members. Predictive testing for asymptomatic relatives should only be pursued after informed consent and appropriate counselling.
Important Clinical Advisory
Do not discontinue, initiate, or adjust any prescribed medication or therapy without explicit instruction from your treating physician. Genetic test results complement clinical decision-making but are not a substitute for medical supervision. Always consult your neurologist or primary care provider before making changes to your care plan.
Exclusion Criteria & Essential Safety Information
- Testing on minors requires a court-approved medical guardian consent document, compliant with UAE personal data protection regulations.
- Acute febrile illness or recent blood transfusion (within 2 weeks) may delay sample collection; reschedule if applicable.
- Whole blood sample must be drawn by a trained phlebotomist under aseptic conditions. Home collection is available daily from 8 AM to 11 PM via VIP Mobile Phlebotomy with temperature-controlled cold-chain logistics.
- Emergency red flags: If you experience sudden, severe dystonic spasms, breathing difficulty, or loss of consciousness, proceed to the nearest emergency department immediately. This test is not a substitute for acute medical care.
- Pregnant individuals may undergo testing after consultation; genetic counselling remains mandatory.
Patient FAQ & Clinical Guidance
1. What does a positive PRKRA gene result mean for me or my child?
A positive result confirms the presence of a disease-causing variant linked to DYT16 dystonia-parkinsonism. Clinical expression varies significantly, and neurological evaluation is essential for correlating genotype with phenotype. Predictive testing for asymptomatic family members should only be undertaken after genetic counselling.
2. How is the sample collected, and is home collection available across the UAE?
A single blood draw (peripheral whole blood) or an FTA card sample is collected by a DHA-licensed phlebotomist at your home between 8 AM and 11 PM daily. The sample is transported using ISO-certified temperature-controlled cold-chain logistics to ensure integrity. Alternatively, extracted DNA from a medical facility may be accepted.
3. Can I use my health insurance, and how do I verify coverage?
Direct billing is available with many major UAE health insurers. Send a copy of your insurance card via WhatsApp to +971 54 548 8731 for immediate eligibility verification and benefit confirmation. Our team will guide you through the pre-authorization process where required.
4. What happens after the test is complete and results are ready?
Your results will be reviewed by a consultant medical geneticist and a detailed clinical report will be issued. A telephonic or in-person genetic counselling session will be scheduled to explain the findings, discuss implications for family members, and outline next steps for management or surveillance.
5. Is this test suitable for children or for prenatal diagnosis?
Testing in minors requires appropriate legal guardian consent and court approval where mandated. Prenatal testing is possible but must be coordinated with a maternal-fetal medicine specialist and genetic counsellor. All testing is conducted in compliance with UAE health data protection frameworks.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient information is encrypted, access-controlled, and used solely for diagnostic purposes with explicit consent.
Clinical Safety: Laboratory procedures and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring the highest standards of clinical accountability and patient safety.
Certification: The testing laboratory operates under an ISO 9001:2015 quality management system and is licensed by the Dubai Health Authority (DHA) under Facility License Number 1143.
Clinical & Logistical Metadata
| Test Name | PRKRA Gene DYT16 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 14โ21 Business Days |
| Sample Type / Matrix | Peripheral whole blood (EDTA), FTA card, or extracted genomic DNA |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | G24.1 |
| LOINC Code | 52042-9 |
| DHA Facility License & Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians